SNIBE Unveils Compact Laboratory Automation Solution at WHX Labs Dubai
Posted on 13 Feb 2026
At WHX Labs Dubai 2026, SNIBE is showcasing its next-generation assay technologies and total laboratory automation (TLA) solutions at Booth S3.B30 under the theme “Operational Excellence.” During the event, the company launched the compact SATLARS Mini T8 system, introduced its rebranded Snibe-NACA technology, and hosted a series of in-depth educational workshops.
SNIBE has unveiled the newest addition to its SATLARS total laboratory automation (TLA) solution at WHX Labs Dubai 2026. The SATLARS Mini T8 is a compact TLA automation system designed to deliver a fully automated workflow from sample processing through cold storage, all within a footprint of approximately 2.2 m². The Mini T8 integrates sample handling, aliquoting, analysis connectivity, and cold storage into a single solution intended for laboratories where space optimization and workflow efficiency are critical.
Additionally, the company is presenting its newly named Snibe-NACA (Noncompetitive Anti-Immune Complex Assay) Technology. The technology is designed to enable sandwich detection of small molecules using anti-immune complex antibodies, overcoming limitations traditionally associated with competitive assay formats. The approach supports improved specificity, linearity, and analytical performance while maintaining the high-throughput advantages of chemiluminescence immunoassay (CLIA) systems.
During the exhibition, SNIBE welcomed senior representatives from Dubai Health Authority and Dubai Health: Dr. Alawi Alsheikh Ali, Director General of Dubai Health Authority, and Dr. Amer Sharif, CEO of Dubai Health. During their visit to the company’s booth, they reviewed SNIBE’s automation and assay technologies, including the newly launched SATLARS Mini T8 system.
Beyond the exhibition floor, SNIBE hosted a series of educational workshops titled “Advancing Laboratory Medicine: Innovation, Automation, and Excellence in Modern Diagnostics”. The sessions addressed clinical and operational topics including serum tumor markers, primary aldosteronism, congenital adrenal hyperplasia, and celiac disease diagnostics, alongside discussions on large-scale laboratory management and total laboratory automation implementation. The sessions emphasized scaling quality in high-volume networks and mastering large-scale laboratory operations exceeding 20,000 tests daily.
The first workshop session took place on the morning of February 10 and featured an international panel led by Tomris Ozben, President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and Marwan Shalaby, CEO of Shalaby Healthcare Ltd. Additional speakers included David Starostka from Hospital Havirov, Houqing Zhou of Fuwai Shenzhen Hospital, and Sabina Ibrahimova, Head of the Laboratory at Customs Hospital. Panel discussions spanned cardiovascular and endocrine disorders, highlighting the critical link between advanced diagnostic technology and precision medicine.
A second session on the afternoon of February 10 brought together another distinguished group of international experts. Clinical leadership perspectives were shared by Alap Christy, Head of Global Reference Labs at Metropolis Healthcare Limited, and Rizwan Uppal, Founding Chairman and CEO of Islamabad Diagnostic Centre.
They were joined by healthcare executives including Mohammad Al Zubaidy, Deputy CEO of Josante Healthcare, and Shakti Aggarwal, Vice President at Krsnaa Diagnostics, who focused on scaling quality and managing large laboratory operations. Additional clinical and operational insights during this session were provided by Hasaf Kolakkadan, Laboratory Director at Medcare Royal Specialty Hospital; Etem Özkaya, Founder of Viromed Laboratories; and Shiefa Sequeira, Division Operations Manager at Dubai Health.
Related Links:
SNIBE
